- Home
- THRD vs DFP Comparison
THRD vs DFP Comparison
Compare THRD & DFP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THRD
- DFP
- Stock Information
- Founded
- THRD 2019
- DFP 2013
- Country
- THRD United States
- DFP United States
- Employees
- THRD N/A
- DFP N/A
- Industry
- THRD Biotechnology: Pharmaceutical Preparations
- DFP Investment Managers
- Sector
- THRD Health Care
- DFP Finance
- Exchange
- THRD Nasdaq
- DFP Nasdaq
- Market Cap
- THRD 512.9M
- DFP 418.2M
- IPO Year
- THRD 2022
- DFP N/A
- Fundamental
- Price
- THRD $13.93
- DFP $20.67
- Analyst Decision
- THRD Strong Buy
- DFP
- Analyst Count
- THRD 3
- DFP 0
- Target Price
- THRD $20.33
- DFP N/A
- AVG Volume (30 Days)
- THRD 184.1K
- DFP 56.2K
- Earning Date
- THRD 11-07-2024
- DFP 01-01-0001
- Dividend Yield
- THRD N/A
- DFP 6.73%
- EPS Growth
- THRD N/A
- DFP N/A
- EPS
- THRD N/A
- DFP N/A
- Revenue
- THRD N/A
- DFP N/A
- Revenue This Year
- THRD N/A
- DFP N/A
- Revenue Next Year
- THRD N/A
- DFP N/A
- P/E Ratio
- THRD N/A
- DFP N/A
- Revenue Growth
- THRD N/A
- DFP N/A
- 52 Week Low
- THRD $5.82
- DFP $15.45
- 52 Week High
- THRD $16.94
- DFP $19.31
- Technical
- Relative Strength Index (RSI)
- THRD 54.76
- DFP 44.31
- Support Level
- THRD $11.69
- DFP $20.25
- Resistance Level
- THRD $14.64
- DFP $21.44
- Average True Range (ATR)
- THRD 0.99
- DFP 0.18
- MACD
- THRD -0.04
- DFP -0.00
- Stochastic Oscillator
- THRD 67.67
- DFP 43.46
About THRD Third Harmonic Bio Inc.
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.
About DFP Flaherty & Crumrine Dynamic Preferred and Income Fund Inc.
Flaherty & Crumrine Pref&Inc Allocation is a diversified, closed-end management investment company. Its investment objective is to seek total return, with an emphasis on high current income.